Overview

Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborator:
Bayer